Please assess the completion status of the following clinical trial:

Trial Title: Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment~* At least one high-risk cytogenetic feature defined by the presence of 17p deletion, 11q deletion and/or p53 mutation~* Eastern Cooperative Oncology Group (ECOG) score of 0 to 2~Exclusion Criteria:~* Any major surgery, chemotherapy or immunotherapy within the last 21 days~* Evidence of hepatitis B virus, hepatitis C virus or known human immunodeficiency virus (HIV) infection~* Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded~* Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)~* Previous therapy with ibrutinib, or any drug that specifically inhibits Bruton's tyrosine kinase (BTK)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ublituximab + Ibrutinib (Type: EXPERIMENTAL): Participants will receive ublituximab intravenous (IV) infusion, up to 150 milligrams (mg) once on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1 (Cycle duration=28 days) followed by 900 mg on Day 1 of Cycles 2 to 6 and 900 mg on Day 1 of every 3rd cycle thereafter for up to 62 months along with ibrutinib 420 mg capsules, orally, once daily (QD) in each 28-day cycle for up to 62 months.
- Ibrutinib (Type: ACTIVE_COMPARATOR): Participants will receive ibrutinib 420 mg capsules, orally, QD in each 28-day cycle up to 62 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).